Skip to main content
FDA accelerates review of Fujirebio's Alzheimer's test
2/15/2019

Miraca Holdings subsidiary Fujirebio Diagnostics' Lumipulse G β-Amyloid Ratio quantitative in vitro diagnostic test for Alzheimer's disease has been granted breakthrough device status by the FDA.

Full Story: